Shares of Horizon Therapeutics /zigman2/quotes/206690250/composite HZNP -0.07% gained 7% in premarket trading on Monday following a positive recommendation for its experimental eye drug from a Food and Drug Administration advisory committee on Friday. The committee voted 12-0 in favor of the FDA approving teprotumumab as a treatment for thyroid eye disease (TED), a rare autoimmune disorder. "Teprotumumab approval seems unquestionable, with discussions leading to a conclusion of allowing maximum access to finally give TED patients a real option," Stifel analysts wrote Dec. 16. The FDA is expected to decide whether to approve the biologic medication by March 8. The regulator is not required to follow the recommendation of the committee but it often does. Horizon's stock is up 54% year-to-date; the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.54% has gained 26%.